{"entity":{"id":"abx-001","kind":"drug","name":"ABX-001","aka":[],"tldr":"ABX-001 is an experimental arenavirus-based non-lytic viroimmunotherapy from Abalos Therapeutics, in phase 1 trials for advanced solid tumours.","summary":"ABX-001 is an arenavirus-based non-lytic viroimmunotherapy (intravenous) from Abalos Therapeutics. An arenavirus-based candidate given into a vein, designed to persist and replicate in cancer cells and antigen-presenting cells without destroying them, triggering innate and adaptive immune responses against the tumour. Its furthest stage is phase 1, for advanced solid tumours (refractory or relapsed). ClinicalTrials.gov registers it in one study linked below. First patient dosed 23 October 2025 (company release); NCT07231458 recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Abalos Therapeutics: abalos-tx.com","url":"https://abalos-tx.com/"},{"label":"Abalos Therapeutics: abalos-tx.com","url":"https://abalos-tx.com/therapeutic-approach/"},{"label":"Abalos Therapeutics: abalos-tx.com","url":"https://abalos-tx.com/wp-content/uploads/2025/10/20251023_Abalos_PR_FPI_ABX-001_Final.pdf"},{"label":"Abalos Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07231458"},{"label":"ClinicalTrials.gov: trials of ABX-001","url":"https://clinicaltrials.gov/search?intr=ABX-001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abalos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07231458"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ABX-001","modality":"Arenavirus-based non-lytic viroimmunotherapy (intravenous)","mechanism":"An arenavirus-based candidate given into a vein, designed to persist and replicate in cancer cells and antigen-presenting cells without destroying them, triggering innate and adaptive immune responses against the tumour.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/abx-001/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"abalos-therapeutics","kind":"company","name":"Abalos Therapeutics","route":"/companies/abalos-therapeutics/"}],"trial":[{"id":"nct07231458","kind":"trial","name":"A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies","route":"/trials/nct07231458/"}]}}